Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data

Diabetes Therapy

Volumn 5, Issue 2, 2014, Pages 471-482

  Bujac, Sarah ^a   Del Parigi, Angelo ^a   Sugg, Jennifer ^a   Grandy, Susan ^a   Liptrot, Tom ^a,c   Karpefors, Martin ^b   Chamberlain, Chris ^a,d   Boothman, Anne Marie ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UCB Celltech   (United Kingdom)

Author keywords

Dapagliflozin; Data mining; Fasting plasma glucose; Machine learning; Meta analysis; Predictor; Prognostic factors; Response profiling; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT RESPONSE; VALIDATION PROCESS;

EID: 84919633907     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0090-y     Document Type: Article

References (26)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
2. Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118:1383–93.
3. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–59.
4. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875–83.
5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.
6. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–24.
7. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.
8. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.
9. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.
10. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–56.
11. Ozery-Flato M, Parush N, El-Hay T, et al. Predictive models for type 2 diabetes onset in middle-aged subjects with the metabolic syndrome. Diabetol Metab Syndr. 2013;5:36.
12. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.
13. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
14. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
15. Cefalu WT, Leiter LA, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension. Diabetes. 2012;61(suppl 1):A271. (Abstract 1056-P).
16. Jabbour S, Hardy E, Sugg JE, Parikh SJ. Dapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study. Diabetes. 2012;61(suppl 1):A275–6. (Abstract 1071-P).
17. Leiter LA, Cefalu WT, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Efficacy and safety of dapagliflozin for type 2 diabetes mellitus patients with a history of cardiovascular disease. Diabetes. 2012;61(suppl 1):A287. (Abstract 1114-P).
18. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.
19. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–15.
20. Freund Y, Schapire RE. Experiments with a new boosting algorithm. In: Saitta L, editor. Machine Learning: Proceedings of the Thirteenth International Conference (ICML ‘96). Burlington: Morgan Kaufmann Publishers; 1996. p. 156–8.
21. Friedman JH. Greedy functions approximation: a gradient boosting machine. Ann Stat. 2001;29:1189–232.
22. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc B Stat Methodol. 2005;67:301–20.
23. Rossi PE, Alenby GM, McCulloch R. Bayesian statistics and marketing. Chichester: Wiley; 2005.
24. Gerich JE, Bastien A. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2011;4:669–83.
25. Bristol-Myers Squibb, AstraZeneca. Forxiga Product Information. Australian Government Department of Health and Ageing-Therapeutic Goods Administration website. http://www.tga.gov.au/pdf/auspar/auspar-dapagliflozin-propanediol-monohydrate-130114-pi.pdf. Accessed July 8, 2013.
26. Bailey CJ, Iqbal N, T’joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951–9.